|Bid||1.67 x 4000|
|Ask||1.74 x 28000|
|Day's Range||1.57 - 1.72|
|52 Week Range||1.57 - 6.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper
LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. Based on this milestone and under the terms of the agreement, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck. "We continue to deliver on all milestones with our existing partners." said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Agenus (AGEN) delivered earnings and revenue surprises of 36.84% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 24 cents. The company's shares closed at $1.75. A year ago, they were trading at $3.85. _____ This story was generated ...
- Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. To listen ...
LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cadence ...
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
LEXINGTON, Mass., July 16, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies1, today announced the appointment of I-O drug development experts into key leadership positions. These appointments will help advance multiple clinical programs and planned BLA filings by 2020. Drs. Gupta and Wijatyk have had successful careers leading the approvals of immune therapies and chemotherapies," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. Dr. Sunil Gupta joins Agenus as Vice President of Regulatory and Pharmacovigilance. Dr. Gupta is a trained oncologist with nearly 30 years in senior leadership positions in clinical development and regulatory affairs.
LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites ...
National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up
LEXINGTON, Mass., June 12, 2018 /PRNewswire/ -- A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discovery to its proprietary next generation anti-CTLA-4 antibody (AGEN1181) on track for IND filing in 2H2018. The pre-clinical study reports on a unique mechanism discovered by Agenus, that can significantly improve the biological and immunological activity of certain cancer fighting antibodies, such as those targeting CTLA-4 and TIGIT.
In today's pre-market research, WallStEquities.com evaluates Affimed N.V. (NASDAQ: AFMD), Agenus Inc. (NASDAQ: AGEN), Akcea Therapeutics Inc. (AKCA), and Akebia Therapeutics Inc. (NASDAQ: AKBA). The Company's shares are trading 8.38% above their 200-day moving average.
Presentation Time and Location: Thursday, Jun 7 at 4:30-4:55 PM EDT in Ballroom to be followed by a breakout session at 5:00-05:25 PM EDT in Uris. A live audio webcast will be accessible on the "Events & Presentations" section of the Company's investor website at www.agenusbio.com where a replay will also be available following the presentation.
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- AGEN1884 and AGEN2034 produce clinical benefit2 in 31% and 42% of patients respectively - Combination trial of AGEN1884 plus AGEN2034 in 2L cervical cancer ongoing to support BLA LEXINGTON, Mass. , June ...
A few FDA approvals and the impending 2018 American Society of Clinical Oncology annual meeting gave some impetus to the biotech space in the week ending June 1. The FDA greenlighted Pfizer Inc. (NYSE: ...